SI2231189T1 - A delivery system for administering pharmaceutical active substances that are poorly soluble in water - Google Patents
A delivery system for administering pharmaceutical active substances that are poorly soluble in water Download PDFInfo
- Publication number
- SI2231189T1 SI2231189T1 SI200831891T SI200831891T SI2231189T1 SI 2231189 T1 SI2231189 T1 SI 2231189T1 SI 200831891 T SI200831891 T SI 200831891T SI 200831891 T SI200831891 T SI 200831891T SI 2231189 T1 SI2231189 T1 SI 2231189T1
- Authority
- SI
- Slovenia
- Prior art keywords
- delivery system
- drug delivery
- substance
- sodium salt
- methyl ester
- Prior art date
Links
- 238000012377 drug delivery Methods 0.000 title claims abstract 13
- 239000013543 active substance Substances 0.000 title claims abstract 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract 4
- 239000003814 drug Substances 0.000 claims abstract 10
- 239000002245 particle Substances 0.000 claims abstract 8
- 238000002360 preparation method Methods 0.000 claims abstract 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract 3
- 201000011510 cancer Diseases 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 159000000000 sodium salts Chemical class 0.000 claims 8
- XVOYSCVBGLVSOL-UHFFFAOYSA-N L-cysteine sulfonic acid Natural products OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 claims 7
- 239000000126 substance Substances 0.000 claims 7
- -1 cysteic acid methyl ester Chemical class 0.000 claims 5
- 229940123237 Taxane Drugs 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 2
- 239000000824 cytostatic agent Substances 0.000 claims 2
- 230000001085 cytostatic effect Effects 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims 2
- 230000001861 immunosuppressant effect Effects 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002296 dynamic light scattering Methods 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 239000013618 particulate matter Substances 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SE2007/001127 WO2009078754A1 (en) | 2007-12-19 | 2007-12-19 | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
| PCT/SE2008/051515 WO2009078802A1 (en) | 2007-12-19 | 2008-12-18 | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
| EP08861526.5A EP2231189B1 (en) | 2007-12-19 | 2008-12-18 | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2231189T1 true SI2231189T1 (en) | 2018-03-30 |
Family
ID=40795732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200831891T SI2231189T1 (en) | 2007-12-19 | 2008-12-18 | A delivery system for administering pharmaceutical active substances that are poorly soluble in water |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US8999382B2 (enExample) |
| EP (1) | EP2231189B1 (enExample) |
| JP (1) | JP5466172B2 (enExample) |
| KR (1) | KR101572703B1 (enExample) |
| CN (1) | CN101951956B (enExample) |
| AU (1) | AU2008339099B2 (enExample) |
| BR (1) | BRPI0821740B1 (enExample) |
| CA (1) | CA2709266C (enExample) |
| CY (2) | CY1119805T1 (enExample) |
| DK (1) | DK2231189T3 (enExample) |
| EA (1) | EA015247B1 (enExample) |
| ES (1) | ES2650242T3 (enExample) |
| FR (1) | FR19C1030I1 (enExample) |
| HR (1) | HRP20171796T1 (enExample) |
| HU (1) | HUE034684T2 (enExample) |
| LT (2) | LT2231189T (enExample) |
| LU (1) | LUC00117I2 (enExample) |
| MX (1) | MX2010006914A (enExample) |
| MY (2) | MY157187A (enExample) |
| NL (1) | NL300987I9 (enExample) |
| NO (2) | NO2231189T3 (enExample) |
| NZ (1) | NZ586859A (enExample) |
| PL (1) | PL2231189T3 (enExample) |
| PT (1) | PT2231189T (enExample) |
| SI (1) | SI2231189T1 (enExample) |
| WO (2) | WO2009078754A1 (enExample) |
| ZA (1) | ZA201004685B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009078755A1 (en) | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
| WO2009078756A1 (en) | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
| WO2009078754A1 (en) * | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
| AU2010239689A1 (en) * | 2009-04-21 | 2011-11-03 | Selecta Biosciences, Inc. | Immunonanotherapeutics providing a Th1-biased response |
| CN107029223A (zh) | 2010-05-26 | 2017-08-11 | 西莱克塔生物科技公司 | 合成纳米载体联合疫苗 |
| EP2640190A4 (en) | 2010-11-05 | 2016-05-11 | Selecta Biosciences Inc | MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS |
| CN103908432B (zh) * | 2013-01-02 | 2018-09-21 | 博瑞生物医药（苏州）股份有限公司 | 一种伊沙匹隆白蛋白的冻干组合物及其制备方法 |
| CN112239418B (zh) * | 2019-07-18 | 2023-07-07 | 上海现代药物制剂工程研究中心有限公司 | 视黄醇类化合物及其钠盐的制备方法 |
| CN112321465B (zh) | 2019-07-18 | 2023-06-06 | 上海现代药物制剂工程研究中心有限公司 | 一种含苯基化合物、其中间体、制备方法及应用 |
| WO2021259472A1 (en) * | 2020-06-24 | 2021-12-30 | Oasmia Pharmaceutical Ab | Micellar docetaxel for use in the treatment of cancer |
| CN115429886B (zh) * | 2021-06-02 | 2025-10-31 | 复旦大学 | 一种药物纳米结晶制剂及其制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| DE19839566C2 (de) * | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
| US6197809B1 (en) * | 1998-12-23 | 2001-03-06 | Ardenia Investments Ltd. | Compounds for the treatment of cancer |
| US6656504B1 (en) * | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
| SE0101702D0 (sv) * | 2001-05-15 | 2001-05-15 | Ardenia Investments Ltd | Novel potentiating compounds |
| US20050191359A1 (en) * | 2001-09-28 | 2005-09-01 | Solubest Ltd. | Water soluble nanoparticles and method for their production |
| US20050249786A1 (en) * | 2001-09-28 | 2005-11-10 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds |
| CN100360502C (zh) * | 2002-07-23 | 2008-01-09 | 阿登尼亚投资有限公司 | 视黄醇衍生物、它们在治疗癌症和增强其它细胞毒性剂功效中的应用 |
| SE0202311D0 (sv) * | 2002-07-23 | 2002-07-23 | Ardenia Investments Ltd | Novel compounds, cytotoxic preparations comprising said compounds, methods of manufacture of said preparations, as well as methods of treatment |
| US7259984B2 (en) * | 2002-11-26 | 2007-08-21 | Cornell Research Foundation, Inc. | Multibit metal nanocrystal memories and fabrication |
| JP2006199590A (ja) | 2003-09-04 | 2006-08-03 | Nano Career Kk | 水溶性の塩基性薬物内包ナノ粒子含有組成物 |
| US20050196343A1 (en) | 2004-02-27 | 2005-09-08 | Molecular Therapeutics, Inc. | Degradable nanoparticles |
| US7871632B2 (en) | 2004-07-12 | 2011-01-18 | Adventrx Pharmaceuticals, Inc. | Compositions for delivering highly water soluble drugs |
| US8945629B2 (en) * | 2004-09-10 | 2015-02-03 | University Of Wyoming | Nanoparticles for cytoplasmic drug delivery to cancer cells |
| CN101291658B (zh) * | 2005-08-31 | 2014-04-16 | 阿布拉科斯生物科学有限公司 | 用于制备稳定性增加的水难溶性药物的组合物和方法 |
| WO2009078755A1 (en) * | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
| WO2009078756A1 (en) * | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
| WO2009078754A1 (en) * | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
-
2007
- 2007-12-19 WO PCT/SE2007/001127 patent/WO2009078754A1/en not_active Ceased
-
2008
- 2008-12-18 PL PL08861526T patent/PL2231189T3/pl unknown
- 2008-12-18 NO NO08861526A patent/NO2231189T3/no unknown
- 2008-12-18 EP EP08861526.5A patent/EP2231189B1/en active Active
- 2008-12-18 KR KR1020107015610A patent/KR101572703B1/ko active Active
- 2008-12-18 PT PT88615265T patent/PT2231189T/pt unknown
- 2008-12-18 WO PCT/SE2008/051515 patent/WO2009078802A1/en not_active Ceased
- 2008-12-18 CA CA2709266A patent/CA2709266C/en active Active
- 2008-12-18 CN CN2008801270180A patent/CN101951956B/zh active Active
- 2008-12-18 DK DK08861526.5T patent/DK2231189T3/en active
- 2008-12-18 MY MYPI2010002786A patent/MY157187A/en unknown
- 2008-12-18 BR BRPI0821740-8A patent/BRPI0821740B1/pt active IP Right Grant
- 2008-12-18 SI SI200831891T patent/SI2231189T1/en unknown
- 2008-12-18 LT LTEP08861526.5T patent/LT2231189T/lt unknown
- 2008-12-18 NZ NZ586859A patent/NZ586859A/en unknown
- 2008-12-18 MX MX2010006914A patent/MX2010006914A/es active IP Right Grant
- 2008-12-18 US US12/809,252 patent/US8999382B2/en active Active
- 2008-12-18 JP JP2010539385A patent/JP5466172B2/ja active Active
- 2008-12-18 AU AU2008339099A patent/AU2008339099B2/en active Active
- 2008-12-18 ES ES08861526.5T patent/ES2650242T3/es active Active
- 2008-12-18 HU HUE08861526A patent/HUE034684T2/en unknown
- 2008-12-18 MY MYPI2010002787A patent/MY157186A/en unknown
- 2008-12-18 EA EA200802350A patent/EA015247B1/ru unknown
- 2008-12-18 HR HRP20171796TT patent/HRP20171796T1/hr unknown
-
2010
- 2010-07-02 ZA ZA2010/04685A patent/ZA201004685B/en unknown
-
2015
- 2015-02-27 US US14/633,177 patent/US9993438B2/en not_active Ceased
-
2017
- 2017-12-04 CY CY20171101264T patent/CY1119805T1/el unknown
-
2019
- 2019-04-24 CY CY2019021C patent/CY2019021I1/el unknown
- 2019-04-25 LT LTPA2019508C patent/LTPA2019508I1/lt unknown
- 2019-05-03 LU LU00117C patent/LUC00117I2/fr unknown
- 2019-05-06 FR FR19C1030C patent/FR19C1030I1/fr active Active
- 2019-05-06 NL NL300987C patent/NL300987I9/nl unknown
- 2019-05-08 NO NO2019023C patent/NO2019023I1/no unknown
-
2020
- 2020-06-12 US US16/899,848 patent/USRE49741E1/en active Active
-
2021
- 2021-02-17 US US17/177,550 patent/USRE49742E1/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Qu et al. | Docetaxel-loaded human serum albumin (HSA) nanoparticles: synthesis, characterization, and evaluation | |
| Lu et al. | Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation | |
| Cheng et al. | The optimized drug delivery systems of treating cancer bone metastatic osteolysis with nanomaterials | |
| Moreno et al. | Pharmacodynamics of cisplatin-loaded PLGA nanoparticles administered to tumor-bearing mice | |
| ES2435944T3 (es) | Nuevas formulaciones de agentes farmacológicos, métodos para su preparación y métodos para su uso | |
| ES2719093T3 (es) | Composiciones de fármacos poco solubles en agua con mayor estabilidad y métodos para su preparación | |
| US11471422B2 (en) | Stealth, targeted nanoparticles (STN) for oral drug delivery | |
| HRP20171796T1 (hr) | Sustav za unos lijekova, namijenjen primjeni farmaceutski aktivnih tvari slabo topljivih u vodi | |
| US20240366519A1 (en) | Nanoparticle delivery systems | |
| Xu et al. | Thermosensitive hydrogel system assembled by PTX-loaded copolymer nanoparticles for sustained intraperitoneal chemotherapy of peritoneal carcinomatosis | |
| US20190015335A1 (en) | Hepatoprotective particles and systems and methods of use thereof | |
| WO2019135715A1 (en) | Lipid-polymer hybrid nanoparticles | |
| JP2011507838A5 (enExample) | ||
| Lu et al. | Sucrose acetate isobutyrate as an in situ forming system for sustained risperidone release | |
| Gavini et al. | Spray-dried poly (D, L-lactide) microspheres containing carboplatin for veterinary use: in vitro and in vivo studies | |
| KR20110056042A (ko) | 종양세포 표적지향을 위한 나노 입자 및 이의 제조방법 | |
| Pal et al. | Advances in engineering of low molecular weight hydrogels for chemotherapeutic applications | |
| JP2018530606A5 (enExample) | ||
| CN106943379A (zh) | 一种藤黄酸白蛋白纳米粒及其制备方法 | |
| Demirbolat et al. | Development of orally applicable, combinatorial drug–loaded nanoparticles for the treatment of fibrosarcoma | |
| Park et al. | The roles of short and long chain fatty acids on physicochemical properties and improved cancer targeting of albumin-based fattigation-platform nanoparticles containing doxorubicin | |
| Liang et al. | Gemcitabine-based polymer-drug conjugate for enhanced anticancer effect in colon cancer | |
| Karimi et al. | Prolonged local delivery of doxorubicin to cancer cells using lipid liquid crystalline system | |
| CN101945671B (zh) | 用于水溶性阳离子两亲性的药用活性物质给药的药物递送系统 | |
| KR20170031637A (ko) | 고분자 또는 지질, α-리포익산 및 광감작제를 포함하는 약물전달체 |